Integrins as novel drug targets for overcoming innate drug resistance

Current Cancer Drug Targets

Volumn 2, Issue 1, 2002, Pages 37-43

  Damiano, Jason S ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; AG 957; ALPHA3 INTEGRIN; ALPHA5 INTEGRIN; ALPHA6 INTEGRIN; ANTINEOPLASTIC AGENT; BETA1 INTEGRIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IMATINIB; INTEGRIN; MELPHALAN; MITOXANTRONE; PACLITAXEL; PROTEIN KINASE INHIBITOR; PROTEIN P27; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE;

CANCER SURVIVAL; CANCER THERAPY; CELL PROTECTION; CELL TYPE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESISTANCE; DRUG TARGETING; DRUG UTILIZATION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; RADIOSENSITIVITY; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; APOPTOSIS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; HUMANS; INTEGRINS; SIGNAL TRANSDUCTION;

EID: 0036280046     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009023334033     Document Type: Review

References (47)

1. Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein
2. Development and characterization of a melphalan resistant human multiple myeloma cell line
3. Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line
4. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A southwest oncology group study
5. Phase I trial of paclitaxel plus megestrol acetate in patients with refractory ovarian cancer
6. Multidrug resistance transporters and modulation
7. The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone
8. Integrins: Versatility, modulation, and signaling in cell adhesion
9. Signaling by integrin receptors
10. New aspects of integrin signaling in cancer
11. Cell adhesion mediated drug resitance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines
12. Integrin-mediated drug resistance in multiple myeloma
13. Genetic marking shows that Ph+ cells present in autologous marrow of chronic myelogenous leukemia (CML) contributes to relapse after aurologous bone marrow transplants in CML
14. Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and γ-irradiation
15. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo
16. Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death
17. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells
18. Reduction in drug-induced DNA double-strand breaks associated with β1 integrin-mediated adhesion correlates with drug resistance in U937 cells
19. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo
20. VLA-4 mediated adhesion to bone marrow stromal cells confers chemoresistance to adherent lymphoma cells
21. + cells from DNA damage-induced apoptosis
22. The alpha 5 beta I integrin supports survival of cells on fibronectin and up-regulates Bc1-2 expression
23. Soluble integrin ligands and growth factors independently rescue neuroblastoma cells from apoptosis under nonadherent conditions
24. Geometric control of cell life and death
25. KIP1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR)
26. KIP1 induced drug resistance by preventing apoptosis upstream of cytochrome C release and procaspase-3 activation in leukemic cells
27. KIP1
28. Phosphatidylinositol 3-kinase is required for integrin stimulated AKT and raf-I/mitogen-activated protein kinase pathway activation
29. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK antegren study group
30. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease
31. Adams tight-binding inhibitor of the integrin alpha(4)beta(1) blocks antigen-induced airway responses and inflammation in experimental asthma in sheep
32. Isoxazolyl, oxazolyl, and thiazolylpropionic acid derivatieves as potent alpha(4)beta(1) integrin antagonists
33. A pilot trial of vitaxin, a humanized anti-vitronectin receptor (anti alpha V beta 3) antibody in patients with metastatic cancer
34. A nonpeptide integrin antagonist can inhibit epithelial cell ingestion of steptococcus pyogenes by blocking formation of integrin alpha5beta1-fibronectin-M1 protein complexes
35. Structural and functional charactgerization of EMF10, a heterodimeric disintegrin from eristocophis macmahoni venom that selectively inhibits alpha5beta1 integrin
36. Phage libraries displaying cyclic peptides with different ring sizes: Lingand specificities of the RGD-directed integrins
37. Anti-inflammatory activity of c(ILDV-NH(CH2)5CO), a Novel, selective, cyclic peptide inhibitor of VLA-4-mediated cell adhesion
38. Induction of apoptosis of integrin-expressing human prostate cancer cells by cyclic Arg-Gly-Asp peptides
39. Integrin affinity modulation
40. Anti-myeloma activity of pamidronate in vivo
41. Bisphosphonates induce apoptosis in human myeloma cell lines: A novel anti-tumour activity
42. A newly developed biophosphonate, TM529, is a potent apoptosis inducer of human myeloma cells
43. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices
44. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone
45. Molecular therapy for multiple myeloma
46. Inhibition of tumor cell invasion and angiogenesis by motuporamines
47. Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment